Comparison of calcium magnesium ferrite nanoparticles for boosting biohydrogen production.

Dark fermentation (DF) is an eco-friendly process that simultaneously achieves organic matter degradation and obtains hydrogen (H). Nonetheless, low H yield mainly caused by poor activity of key microbes, is still a problem that requires being resolved. In this work, MgFeO and CaMgFeO nanoparticles (NPs) were synthetized and served as additives to boost H form from DF.

Improved biohydrogen evolution through calcium ferrite nanoparticles assisted dark fermentation.

Dark fermentation (DF) is a green hydrogen (H) production process, but it is far below the theoretical H yield. In this study, calcium ferrite nanoparticles (CaFeO NPs) were produced to augment H yield via DF. The highest H yield of 250.

Comparison of copper and aluminum doped cobalt ferrate nanoparticles for improving biohydrogen production.

Two various materials, copper and aluminum doped cobalt ferrite nanoparticles (NPs) were fabricated for investigating their effects of addition amounts on hydrogen (H) synthesis and process stability. CoCuFeONPs enhanced H production more than CoAlFeO NPs under same condition. The highest H yield of 212.

Comparison of mesophilic and thermophilic dark fermentation with nickel ferrite nanoparticles supplementation for biohydrogen production.

In this work, nickel ferrite nanoparticles (NiFeO NPs) was prepared to improve hydrogen (H) production by dark fermentation. Moderate amounts (50-200 mg/L) promoted H generation, while excess NiFeO NPs (over 400 mg/L) lowered H productivity. The highest H yields of 222 and 130 mL/g glucose were obtained in the 100 mg/L (37 °C) and 200 mg/L NiFeO NPs (55 °C) groups, respectively, and the values were 38.

A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.

We previously identified human phosphatidylethanolamine-binding protein 4 (hPEBP4) as an antiapoptotic protein with increased expression levels in breast, ovarian and prostate cancer cells, but low expression levels in normal tissues, which makes hPEBP4 an attractive target for immunotherapy. Here, we developed hPEBP4-derived immunogenic peptides for inducing antigen-specific cytotoxic T lymphocytes (CTLs) targeting breast cancer. A panel of hPEBP4-derived peptides predicted by peptide-MHC-binding algorithms was evaluated to characterize their HLA-A2.